Litcius/Paper detail

CD4+LAG3+T cells are decreased in SSc-ILD and affect fibroblast mesenchymal transition by TGF-β3

Linmang Qin, Haobo Lin, Fu Zhu, Jieying Wang, Tianxiao Feng, Ting Xu, Guangfeng Zhang, Xiao Zhang

2023iScience10 citationsDOIOpen Access PDF

Abstract

Pulmonary fibrosis frequently occurs in rheumatic conditions, particularly systemic sclerosis-associated interstitial lung disease (SSc-ILD). The pathology involves cell transformation into interstitial structures and collagen accumulation. CD4 + LAG3 + T cells, known for immune inhibition, are relevant in autoimmunity. This study investigates CD4 + LAG3 + T cells in SSc-ILD. Clinical analysis revealed a correlation between CD4 + LAG3 + T cells and interleukin-6 (IL-6) and erythrocyte sedimentation rate (ESR). Using primary human lung fibroblasts (pHLFs) and murine bone marrow-derived macrophages (BMDMs), we showed that CD4 + LAG3 + T cells secreted TGF-β3 inhibits TGF-β1-induced mesenchymal transformation, modulates cellular function, and reduces collagen release. In mouse models, CD4 + LAG3 + T cells exhibited potential in alleviating bleomycin-induced pulmonary fibrosis. This study emphasizes CD4 + LAG3 + T cells' therapeutic promise against fibrosis and proposes their role as biomarkers.

Topics & Concepts

Pulmonary fibrosisMesenchymal stem cellIdiopathic pulmonary fibrosisCancer researchFibrosisImmunologyBleomycinInterstitial lung diseaseChemistryImmune systemMedicineLungPathologyInternal medicineChemotherapyInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisIL-33, ST2, and ILC PathwaysSystemic Sclerosis and Related Diseases
CD4+LAG3+T cells are decreased in SSc-ILD and affect fibroblast mesenchymal transition by TGF-β3 | Litcius